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Acute intermittent porphyria is a rare metabolic disorder resulting from a partial 
deficiency of porphobilinogen  deaminase, enzyme in the heme biosynthetic pathway. Its 
inheritance is autosomal dominant. A deficiency of porphobilinogen deaminase is not 
sufficient by its self to produce acute intermittent porphyria, and other activating factors 
must also be present. These include some drugs, hormones, infection, injury and 
alcohol. 
Besides others, anesthetics have been implicated in the triggering of a number of 
severe porphyric reactions. Although there is no clinical evidence, the fear of hypo-
thesized porphyrinogenicity of repetitive anesthetics exposures still remains. Despite 
these doubts, we report here the case of uneventful repeated exposure to anesthetics in 
a patient suffering from acute intermittent porphyria, within a fifteen- month period. On 
both occasions, the patient was safely exposed to certain anesthetics included: propofol, 
sevoflurane, rocuronium, midazolam and fentanyl. Acta Medica Medianae 2010;49(3): 
55-57. 
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Introduction 
 
Acute intermittent porphyria (AIP) is a rare 
metabolic disorder resulting from a partial 
deficiency of porphobilinogen deaminase (PBGD), 
enzyme in the heme biosynthetic pathway. Its 
inheritance is autosomal dominant. Most people 
who inherit the gene for AIP never develop 
symptoms. A deficiency of PBGD is not sufficient 
by its self to produce AIP and other activating 
factors must also be present. In some people, 
however, certain factors can precipitate symptoms, 
producing an attack. Many drugs, sex hormones,  
low-calories and low-carbohydrate diets, ingestion 
of alcohol, mental stress or some infection are 
sometime implicated. Sometimes, the factors 
that cause an attack cannot be identified. Attacks 
are more common in women than in men, and 
occur only and very rarely before puberty. Symptoms 
may include acute onset of vomiting, abdominal 
or back pain, weakness in arms or legs, and 
mental symptoms, which are common, from 
irritation, restlessness, insomnia, and agitation to 
tiredness and depression. 
Some authors suggested that repeated 
exposure to anesthetics may prove to be 
hazardous in acute intermittent porphyria (AIP)
 
(1). With the exception of propofol, there are no 
published reports considering the safety of the 
repeated exposures to anesthetics in the patient 
suffering from AIP. Therefore, we report the case 
of repeated and prolonged exposure to certain 
anesthetics including: midazolam, propofol, rocu-
ronium, fentanyl and sevoflurane in the same 
patient suffering from AIP.  
 
Table 1. Anesthetic managements and total anesthetics consumption 
 
Anesthetics  First anesthesia  Second anesthesia 
Midazolam (mg)  7  7 
Fentanyl (µg)  250  300 
Rocuronium (mg)  60  100 
Propofol (mg)  180  200 
Sevoflurane (et vol. %)  1.6 - 2.5  1.3 – 2.8 
Total anesthesia duration (min)  52 98 Anesthetic management for a patient with acute intermittent porphyria                                         Angelina Bogićević i sar. 
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 Case  presentation 
 
A 42-year-old female weighing 68 kg was 
primarily admitted for elective breast tumorectomy. 
After fifteen months, she had another medical 
procedure. This time, the procedure involved bilateral 
subcutaneous mastectomy together with primary 
reconstruction and implantation of breast implants 
(CPG Medium Gel Breast Implant Cohesive III a 
355cc - Mentor
®). Eleven years prior to the initial 
admission, she developed an acute quadriplegia 
following pregnancy, and was diagnosed as 
having an AIP. At the time of the admissions the 
patient was presented with the remaining 
bilateral peroneal paresis, but had no symptoms 
of an acute attack of porphyria. Her clinical 
condition was optimal. Examination of the urine 
for porphyrins confirmed the diagnosis of AIP – 
the Watson-Schwartz test was positive (+). 
Both surgical procedures were performed 
under general anesthesia with similar managements 
(Table 1). Midazolam (0.1 mg
.kg
-1), used for pre-
medication and rocuronium (0.6 mg
.kg
-1) were given 
under neuromuscular blockade monitoring (TOF 
Watch S–Organon Ireland LTD
®) to facilitate 
endotraheal intubation and to provide the surgical 
relaxation. The first anesthesia was induced with 
fentanyl 150 µg and propofol 180 mg. In the 
same way, the following anesthesia was induced 
by fentanyl 200 µg and propofol 200 mg. On both 
occasions anesthesia was maintained by sevoflurane 
at an end-tidal concentration of 1.3–2.8% in 50% 
N2O supplemented by intermittent boluses of 
fentanyl. Collectively, the patient received in total 
380 mg of propofol and was exposed to continuous 
sevoflurane inhalation for the duration of 2.5 
hours. Postoperative analgesia was provided by 
ketorolac 30 mg every 6 hours. The patient was 
supplied with sufficient amounts of glucose solutions 
in order to avoid a hypoglycemic state during 
perioperative and early postoperative period. 
Both perioperative courses were uneventful, the 
patient exhibited no signs of an acute porphyric 
crisis and was discharged home as per routine. 
 
Discussion  
 
  AIP is an autosomal dominant disorder of 
heme biosynthesis caused by molecular defects 
in the porphobilinogen (PBG) deaminase gene 
which then lead to the accumulation of the heam 
precursors: PBG and δ-aminolaevulinic acid (ALA). 
Besides others, anesthetics have been
 implicated 
in the triggering of a number of severe porphyric
 
reactions. Although there is no clinical evidence, 
the fear of hypothesized porphyrinogenicity of 
repetitive anesthetics exposures still remains.     
  Propofol is considered, being safe as a drug 
for both induction and for maintenance of anesthesia 
for patients with AIP (1). Although some reports 
showed elevated porphyrins following continuous 
infusions or repeated propofol exposure, this was 
not accompanied by any porphiric symptoms. In 
the aforementioned, total doses of 900 and 1300 
mg of propofol were administered (2,3). Opposite 
to those findings, Shaw and McKeith presented the 
course of uneventful electroconvulsive treatments 
with propofol as the sole induction agent. In 
seven repetitive treatments, the patient received 
in total 450 mg of propofol within 23-day period 
with no urinary porphirins detected (4). On the 
other hand, the safe repetitive exposures to 
propofol were presented likewise by the Mitter-
schiffthaller et al. (5) and Harrison and McAuley
 
(6). Considering all these findings, there remain 
some doubts about the safety of repeated or 
prolonged exposure to propofol to the patients 
suffering from AIP. We uneventfully administered 
the total 380 mg of propofol on two occasions in 
the same patient. 
  Recently Hsieh et al. reported the safe use 
of rocuronium in AIP (7). It was the first ever 
reported use of rocuronium in this specific 
occasion. Some authors postulated that as with 
propofol, prolonged
  use of rocuronium may not 
be safe (1). Nevertheless, our patient received on 
both occasions a total of 160 mg of rocuronium 
with no clinical or laboratory evidence of its 
porphyrinogenicity. 
  Modern inhalation agents are generally 
considered safe in porphyric patients. Sevoflurane 
has been reported as a safe agent for both 
induction and maintenance of anesthesia (7-9).   
Fast and relatively unchanged elimination and the 
minimal induction of the cytochrome P 450 
system render sevoflurane favorable in this back-
ground. On the contrary, the animal studies strongly 
suggested a significant induction in ALA-synthase 
activity and a reduction of PBG-ase activity following 
administration of volatile anesthetics, which included 
sevoflurane (10). We safely exposed our patient 
to repeated sevoflurane inhalation which lasted 
2.5 hours. Our clinical experience supports the 
opinion that both cell culture and animal models 
tend to overestimate the
  porphyrinogenicity of 
investigated drugs (1). 
  Literature on midazolam and any of
  the 
opiates currently in use suggest they can safely 
be used in AIP (1). 
  Some limitations of our conclusion may be 
derived from insufficient laboratory investigations. 
Regrettably, the semi quantitative Watson-Schwartz 
test for porphyria is only available in our hospital. 
  In conclusion, in spite of uncertainties that 
repeated or prolonged exposure to ane-sthetics 
may
 be hazardous in a c ase of AIP, we s u g g e s t  
that certain anesthetics such as midazolam, propofol, 
rocuronium, fentanyl and sevoflurane might be 
safely used on repetitive occasions in the same 
patient with AIP. 
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SPECIFIČNOSTI ANESTEZIJE KOD BOLESNIKA OBOLELIH OD AKUTNE 
INTERMITENTNE PORFIRIJE 
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Akutna intermitentna porfirija je redak, autozomno dominantno nasledni metabolički 
poremećaj, u či j o j  j e  o s n o v i  p o r e m e ćaj biosinteza hema. Uslovljena je nedostatkom 
enzima porfobilinogen deaminaze, što za posledicu ima nagomilavanje prekursora hema: 
porfobilinogena i δ-aminolevulinske kiseline. Sam nedostatak enzima nije dovoljan za 
pojavu bolesti, jer sem toga moraju biti prisutni i drugi, aktivirajući faktori. Najčešće se 
pominju određeni lekovi, hormoni, infekcija, povrede, gladovanje, alkohol i razni toksini. 
Između ostalih, anesteticima se pripisuje svojstvo okidača teških porfirijskih 
reakcija. Iako ne postoje čvrsti klinički dokazi, strah od pretpostavljenog uticaja 
ponavljanih  ili produženih izlaganja anesteticima kod bolesnika obolelih od porfirije još 
uvek postoji. Nasuprot tome, u ovom članku mi prikazujemo slučaj bezbedne ponovljene 
ekspozicije anesteticima u vremenskom razmaku od petnaest meseci kod bolesnice sa 
dokazanom akutnom intermitentnom porfirijom. Obe hirurške procedure su izvedene u 
opštoj anesteziji, sa sličnom strategijom. Od anestetika su korišćeni: propofol, sevofluran, 
rokuronijum, midazolam i fentanil. Acta Medica Medianae 2010;49(3):55-57. 
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